Ixico (LON:IXI) posted its quarterly earnings results on Monday. The company reported GBX (5.70) (($0.08)) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of GBX (4.90) (($0.07)) by GBX (0.80) (($0.01)), Bloomberg Earnings reports. The company had revenue of £411 million during the quarter. Ixico had a negative return on equity of 35.21% and a negative net margin of 33.90%.
Ixico (LON:IXI) opened at GBX 30 ($0.40) on Monday. Ixico has a 52-week low of GBX 22.20 ($0.30) and a 52-week high of GBX 40.05 ($0.54).
ILLEGAL ACTIVITY WARNING: “Ixico (IXI) Posts Earnings Results, Misses Expectations By $0.80 EPS” was originally published by Stock Observer and is owned by of Stock Observer. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.thestockobserver.com/2017/12/11/ixico-ixi-posts-earnings-results-misses-expectations-by-0-80-eps.html.
IXICO plc is a brain health company. The Company’s brain health focus includes Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, behavioral health and adolescent mental health. It is a provider of clinical trials services to pharmaceutical companies. Its products include Assessa, mehealth, MyBrainBook and TrialTracker.
Receive News & Ratings for Ixico Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ixico Plc and related companies with MarketBeat.com's FREE daily email newsletter.